Back to Search Start Over

European Stroke Organisation guidelines on treatment of patients with intracranial atherosclerotic disease

Authors :
Psychogios, Marios
Brehm, Alex
López-Cancio, Elena
Marco De Marchis, Gian
Meseguer, Elena
Katsanos, Aristeidis H.
Kremer, Christine
Sporns, Peter
Zedde, Marialuisa
Kobayashi, Adam
Caroff, Jildaz
Bos, Daniel
Lémeret, Sabrina
Lal, Avtar
Arenillas, Juan F.
Psychogios, Marios
Brehm, Alex
López-Cancio, Elena
Marco De Marchis, Gian
Meseguer, Elena
Katsanos, Aristeidis H.
Kremer, Christine
Sporns, Peter
Zedde, Marialuisa
Kobayashi, Adam
Caroff, Jildaz
Bos, Daniel
Lémeret, Sabrina
Lal, Avtar
Arenillas, Juan F.
Source :
Psychogios , M , Brehm , A , López-Cancio , E , Marco De Marchis , G , Meseguer , E , Katsanos , A H , Kremer , C , Sporns , P , Zedde , M , Kobayashi , A , Caroff , J , Bos , D , Lémeret , S , Lal , A & Arenillas , J F 2022 , ' European Stroke Organisation guidelines on treatment of patients with intracranial atherosclerotic disease ' , European Stroke Journal , vol. 7 , no. 3 , pp. III-IV .
Publication Year :
2022

Abstract

The aim of the present European Stroke Organisation guideline is to provide clinically useful evidence-based recommendations on the management of patients with intracranial atherosclerotic disease (ICAD). The guidelines were prepared following the Standard Operational Procedure of the European Stroke Organisation guidelines and according to GRADE methodology. ICAD represents a major cause of ischemic stroke worldwide, and patients affected by this condition are exposed to a high risk for future strokes and other major cardiovascular events, despite best medical therapy available. We identified 11 relevant clinical problems affecting ICAD patients and formulated the corresponding Population Intervention Comparator Outcomes (PICO) questions. The first two questions refer to the asymptomatic stage of the disease, which is being increasingly detected thanks to the routine use of noninvasive vascular imaging. We were not able to provide evidence-based recommendations regarding the optimal detection strategy and management of asymptomatic ICAD, and further research in the field is encouraged as subclinical ICAD may represent a big opportunity to improve primary stroke prevention. The second block of PICOs (3–5) is dedicated to the management of acute large vessel occlusion (LVO) ischemic stroke caused by ICAD, a clinical presentation of this disease that is becoming increasingly relevant and problematic, since it is associated with more refractory endovascular reperfusion procedures. An operational definition of probable ICAD-related LVO is proposed in the guideline. Despite the challenging context, no dedicated randomized clinical trials (RCTs) were identified, and therefore the guideline can only provide with suggestions derived from observational studies and our expert consensus, such as the escalated use of glycoprotein IIb-IIIa inhibitors and angioplasty/stenting in cases of refractory thrombectomies due to underlying ICAD. The last block of PICOs is devoted to th

Details

Database :
OAIster
Journal :
Psychogios , M , Brehm , A , López-Cancio , E , Marco De Marchis , G , Meseguer , E , Katsanos , A H , Kremer , C , Sporns , P , Zedde , M , Kobayashi , A , Caroff , J , Bos , D , Lémeret , S , Lal , A & Arenillas , J F 2022 , ' European Stroke Organisation guidelines on treatment of patients with intracranial atherosclerotic disease ' , European Stroke Journal , vol. 7 , no. 3 , pp. III-IV .
Notes :
application/pdf, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1346347646
Document Type :
Electronic Resource